Bridge biotherapeutics' global operation as nrdo
•
0 likes•359 views
Bridge Biotherapeutics's CEO presents his perspective on how to globalize Korean biotech sectors.
Recommended
Recommended
More Related Content
Similar to Bridge biotherapeutics' global operation as nrdo
Similar to Bridge biotherapeutics' global operation as nrdo (20)
More from James Jungkue Lee
More from James Jungkue Lee (15)
Recently uploaded
Recently uploaded (20)
Bridge biotherapeutics' global operation as nrdo
- 1. Bridge Biotherapeutics' Global Operation as NRDO November 13, 2019 Global Market Strategy with SIDLEY, BioPlus 2019 James Jungkue Lee, Bridge Biotherapeutics, Inc.
- 3. Recent Global Licensing Agreement • Total licensing fee : >1.1 billion euro • Near-term payment including upfront : 45 million euro • Running royalty : up to mid-double digit • Phase 2 to be initiated within 12 months. • Time from term sheet issuance to deal closing : 5 months • Partnering with BI, the market leader in IPF 3
- 4. 4 Bridge Biotherapeutics Snapshot 4 Year and 3 Months (2015.10~) Seongnam-si Maryland (USA) JLABS@Shanghai KrW 64billion ($55million) 18 Crews (15 in Korea, 3 in USA) (3 M.D.) 1 License-in / 1 US IND • P2 (Ulcerative colitis) • P1 (Pulmonary fibrosis) • IND-stage (NSCLC) $1.2 billion deal $40 million deal (Cash-burn $20m+/year)
- 5. 5 Pipeline Overview Drug BBT-401 (Pellino-1 Inhibitor) Indication Ulcerative Colitis Discovery Preclinical Phase 1 BBT-877 (Autotaxin Inhibitor) IPF, Others BBT-176 (Targeted Cancer Therapy) NSCLC Phase2 Phase3 US (‘18) US (‘19) China US First-in-Class Potential Best-in-Class
- 6. 6 Bridge Biotherapeutics from DAY ONE • Finding Innovations LOCALLY • Financing REGIONALLY • Developing Compounds GLOBALLY
- 7. 7 Bridge Biotherapeutics from DAY ONE • Finding Innovations LOCALLY • Financing REGIONALLY • Developing Compounds GLOBALLY Ø With Global Perspectives Ø In Major Markets Ø With Talents Around the World
- 9. 9 Global Perspectives • Global Competition • Boundary Conditions • Smaller capital • Smaller pool of accessible innovations • Different investor appetites • Strategy • Small molecule modality for CAPITAL efficiency • TA Out of oncology à Less COMPETITION and clearer LANDSCAPE • First-in-class for extreme DIFFERENTIATION
- 11. • Talents to be externalized • CMC execution • Regulatory and clinical operation • Talents to be internalized • CMC design • Translational research • DMPK/Tox • The best partner of choice • Friendly (better payment terms) • Fast (responsive) 11 Global Talents • IT System • MS Office 365 Cloud • Anytime • Anywhere • Collaborative 11
- 12. confidential 12 World-class Advisory Board (BBT-877) Luca Richeldi Arata AzumaJinwoo SongMartina VasakovaGanesh Raghu Tim Blackwell Fernando MartinezMartin Kolb India China Tamera Corte Esbriet® Lead PI Ofev® Lead PI
- 14. 14 Major Markets • US IND • Science-driven IND review system • 30 days review • China IND • The fastest growing and the second largest market • The biggest patients pool • Rapidly changing regulatory frameworks • Results • Two US INDs • One China IND • One global licensing
- 15. KSF – Team Play - Global playbook - Empowerment - Lean and agile 15 15
- 16. Thanks to science Don’t be overwhelmed 16
- 17. 17 We will stay focused on PATIETNS.
- 18. We will continue to be the best partner of choice to Korean biotech community 18
- 19. Q&A 19